{
    "clinical_study": {
        "@rank": "46826", 
        "acronym": "EXTATIC", 
        "arm_group": [
            {
                "arm_group_label": "patients treated with efavirenz", 
                "description": "HIV-infected on stable HAART regimen with efavirenz"
            }, 
            {
                "arm_group_label": "patients treated with atazanavir", 
                "description": "HIV-infected patients on stable HAART regimen with atazanavir"
            }, 
            {
                "arm_group_label": "patients treated with darunavir", 
                "description": "HIV-infected patients on stable HAART regimen with darunavir"
            }
        ], 
        "brief_summary": {
            "textblock": "The concentration of the third agent in antiretroviral therapy [Non Nucleoside Reverse\n      Transcriptase Inhibitor (NNRTI), or boosted Protease inhibitor (PI) ] is different according\n      to the body weight or body composition and therapeutic monitoring may be necessary in\n      overweight HIV patients.\n\n      The investigators aim at measuring the individual trough concentrations of interest [at\n      steady state for NNRTI and boosted PI] in overweight and normal weight HIV+ patients."
        }, 
        "brief_title": "Antiretroviral Therapy and Extreme Weight", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Our primary endpoint is the individual trough concentrations of interest at steady state for\n      NNRTI or boosted PI; Principal outcome measure: comparison of the concentrations between\n      patients <25kg/m2 and patients<25kg/m2\n\n      Secondary endpoints:\n\n        -  Occurrence of virologic failure\n\n        -  Occurrence of clinical/biological adverse events\n\n        -  Percentage of patients with concentration within the therapeutic range\n\n        -  Body composition Secondary outcome measures: comparison of the occurrence of virologic\n           failure, occurrence or adverse event, patients with concentration within the\n           therapeutic range between groups. Correlation between body composition and\n           concentration.\n\n      Methodology, study design:\n\n      open-labelled monocentric study.\n\n      Sample size:\n\n      It will be a descriptive experimental study involving 120 overweight subjects, 120 normal\n      weight subjects\n\n      Inclusion criteria :\n\n        -  Patients with HIV+\n\n        -  Patients aged more than 18 years old.\n\n        -  Patient giving its well-informed and free consent.\n\n      Study design :\n\n      Plasma concentration was performed during the usual clinical follow-up. Study duration: 12\n      months Duration for a patient: 1 day Investigating center and participating units: one\n      center enrolling the patients and the lab performing drug dosages."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with HIV+ receiving one of the following third agent their HAART: efavirenz,\n             atazanavir , or darunavir\n\n          -  Patients aged > 18 years old.\n\n          -  Patient giving its well-informed and free consent. Patient giving its well-informed\n             and free consent.\n\n        Patients living in France during the study.\n\n        Exclusion Criteria:\n\n        Treatment with rifampin/rifabutin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "HIV-infected patients aged 18 years and older, treated with either efavirenz, atazanavir,\n        or darunavir for at least 4 weeks and under stable treatment regimen"
            }
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01805427", 
            "org_study_id": "EXTATIC", 
            "secondary_id": "EXTATIC"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "trough concentration", 
            "weight", 
            "HIV", 
            "virological failure"
        ], 
        "lastchanged_date": "December 5, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Paris", 
                    "country": "France", 
                    "state": "Ile-de-France", 
                    "zip": "75010"
                }, 
                "name": "Hopital Lariboisiere"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "3", 
        "official_title": "Extreme Weights and Antiretroviral Therapy Individual Concentrations", 
        "other_outcome": {
            "measure": "occurrence of adverse events in each patient group", 
            "safety_issue": "Yes", 
            "time_frame": "the day of enrollment"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "comparison of the trough concentrations between patients with Body Mass Index (BMI)<25 kg/m2 and patients with BMI >25 kg/m2", 
            "safety_issue": "No", 
            "time_frame": "the day of enrollment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01805427"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hopital Lariboisi\u00e8re", 
            "investigator_full_name": "Stephane Mouly, MD PhD", 
            "investigator_title": "MD PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "comparison of the occurrence of virologic failure within each patient group", 
            "safety_issue": "No", 
            "time_frame": "the day of enrollment"
        }, 
        "source": "Hopital Lariboisi\u00e8re", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hopital Lariboisi\u00e8re", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}